rofecoxib has been researched along with Colonic Neoplasms in 11 studies
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells." | 7.96 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimović-Ivanić, D; Mijatović, S; Murganić, B; Neumann, W; Paskaš, S; Pietzsch, J; Sárosi, MB, 2020) |
| " Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells." | 3.96 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimović-Ivanić, D; Mijatović, S; Murganić, B; Neumann, W; Paskaš, S; Pietzsch, J; Sárosi, MB, 2020) |
| "Rofecoxib in lower doses had the same effect on adenomas (p < 0." | 1.33 | Cyclooxygenase-2 inhibition in colon experimental carcinogenesis. ( Amengual Antich, I; Gamundí Gamundí, A; Ibarra de la Rosa, J; Noguera Aguilar, JF; Plaza Martínez, A; Pujol Tugores, JJ; Tortajada Collado, C, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bhardwaj, A | 1 |
| Kaur, J | 1 |
| Sharma, SK | 1 |
| Huang, Z | 1 |
| Wuest, F | 1 |
| Knaus, EE | 1 |
| Buzharevski, A | 1 |
| Paskaš, S | 1 |
| Sárosi, MB | 1 |
| Laube, M | 1 |
| Lönnecke, P | 1 |
| Neumann, W | 1 |
| Murganić, B | 1 |
| Mijatović, S | 1 |
| Maksimović-Ivanić, D | 1 |
| Pietzsch, J | 1 |
| Hey-Hawkins, E | 1 |
| Dovizio, M | 1 |
| Maier, TJ | 2 |
| Alberti, S | 1 |
| Di Francesco, L | 1 |
| Marcantoni, E | 1 |
| Münch, G | 1 |
| John, CM | 1 |
| Suess, B | 1 |
| Sgambato, A | 1 |
| Steinhilber, D | 1 |
| Patrignani, P | 1 |
| Zhang, Y | 1 |
| Hoda, MN | 1 |
| Zheng, X | 1 |
| Li, W | 1 |
| Luo, P | 1 |
| Maddipati, KR | 1 |
| Seki, T | 1 |
| Ergul, A | 1 |
| Wang, MH | 1 |
| Evans, JF | 1 |
| Noguera Aguilar, JF | 2 |
| Plaza Martínez, A | 2 |
| Amengual Antich, I | 2 |
| Morón Canis, JM | 1 |
| Tortajada Collado, C | 2 |
| Pujol Tugores, JJ | 2 |
| Thompson, CA | 1 |
| Janssen, A | 1 |
| Schmidt, R | 1 |
| Geisslinger, G | 1 |
| Grösch, S | 1 |
| Ibarra de la Rosa, J | 1 |
| Gamundí Gamundí, A | 1 |
| Soh, JW | 1 |
| Kazi, JU | 1 |
| Li, H | 1 |
| Thompson, WJ | 1 |
| Weinstein, IB | 1 |
| Ziegler, J | 1 |
11 other studies available for rofecoxib and Colonic Neoplasms
| Article | Year |
|---|---|
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygen | 2013 |
Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.
Topics: Antineoplastic Agents; Boron Compounds; Carcinogenesis; Cell Line, Tumor; Colonic Neoplasms; Cycloox | 2020 |
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells.
Topics: Binding Sites; Blood Platelets; Cell Communication; Cell Line, Tumor; Colonic Neoplasms; Cyclin B1; | 2013 |
Combined therapy with COX-2 inhibitor and 20-HETE inhibitor reduces colon tumor growth and the adverse effects of ischemic stroke associated with COX-2 inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Ischemia; Cell Line, Tumor; Cell Prol | 2014 |
Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Co | 2003 |
Influence of rofecoxib on experimental colonic carcinogenesis in rats.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Carcinogens; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxyg | 2004 |
COX-2 inhibitors still eyed for cancer prevention.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Colonic Neoplasms; Cycl | 2005 |
Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Topics: Adenomatous Polyposis Coli Protein; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents | 2005 |
Cyclooxygenase-2 inhibition in colon experimental carcinogenesis.
Topics: 1,2-Dimethylhydrazine; Animals; Aspirin; Colonic Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2005 |
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G.
Topics: Apoptosis; Celecoxib; Cell Adhesion Molecules; Cell Proliferation; Colonic Neoplasms; Cyclic GMP; Cy | 2008 |
Early trials probe COX-2 inhibitors' cancer-fighting potential.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1999 |